- Report
- May 2026
- 326 Pages
Global
From €5202EUR$5,850USD£4,492GBP
- Report
- May 2026
- 198 Pages
Global
From €5202EUR$5,850USD£4,492GBP
- Report
- May 2026
- 284 Pages
Global
From €5202EUR$5,850USD£4,492GBP
- Report
- April 2026
- 981 Pages
Global
From €7105EUR$7,990USD£6,136GBP
- Report
- January 2026
- 450 Pages
Global
From €4446EUR$5,000USD£3,840GBP
- Report
- January 2026
- 220 Pages
Global
From €2223EUR$2,500USD£1,920GBP
- Report
- January 2026
- 180 Pages
Global
From €4002EUR$4,500USD£3,456GBP
- Report
- March 2026
- 200 Pages
Global
From €2480EUR$2,789USD£2,142GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2480EUR$2,789USD£2,142GBP
- Report
- June 2025
- 150 Pages
Global
From €2400EUR$2,699USD£2,073GBP
- Report
- June 2025
- 200 Pages
Global
From €2480EUR$2,789USD£2,142GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2480EUR$2,789USD£2,142GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2480EUR$2,789USD£2,142GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2480EUR$2,789USD£2,142GBP
- Report
- June 2025
- 400 Pages
Global
From €4401EUR$4,949USD£3,800GBP
- Report
- June 2025
- 280 Pages
Global
From €4442EUR$4,995USD£3,836GBP
- Report
- August 2025
- 150 Pages
Global
From €4313EUR$4,850USD£3,724GBP
- Report
- October 2025
- 160 Pages
Global
From €2986EUR$3,358USD£2,578GBP
€3513EUR$3,950USD£3,033GBP
- Report
- October 2025
- 160 Pages
Global
From €2986EUR$3,358USD£2,578GBP
€3513EUR$3,950USD£3,033GBP
- Report
- October 2025
- 98 Pages
Global
From €3500EUR$4,216USD£3,128GBP

Bevacizumab is a monoclonal antibody used in the treatment of various types of cancer. It is used in combination with other drugs to treat metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, and metastatic breast cancer. Bevacizumab works by inhibiting the growth of new blood vessels, which can help slow the growth of tumors. It is administered intravenously and is typically given in combination with other chemotherapy drugs.
Bevacizumab is a widely used drug in the oncology market, and is one of the most prescribed drugs for cancer treatment. It is used in combination with other drugs to treat a variety of cancers, and is often used in combination with chemotherapy. Bevacizumab has been shown to be effective in treating certain types of cancer, and is generally well tolerated.
Some companies in the Bevacizumab market include Genentech, Roche, Pfizer, Merck, and Bristol-Myers Squibb. Show Less Read more